TP53-mut DLBCL — predicts R-CHOP failure; flag for early CAR-T pathway consideration at 2...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-TP53-MUT-DLBCL-NOS |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-DLBCL-NOS |
| Sources | SRC-CIVIC SRC-ESMO-DLBCL-2024 SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-TP53-MUTATION |
|---|---|
| Variant | any pathogenic mutation OR del(17p) |
| Disease | DIS-DLBCL-NOS |
| ESCAT tier | IIIB |
| Recommended combinations | pola-R-CHP (1L; not TP53-selected), CAR-T axi-cel / liso-cel (2L+) |
| Evidence summary | TP53-mut DLBCL — predicts R-CHOP failure; flag for early CAR-T pathway consideration at 2L+. Not yet driving 1L algorithm; pola-R-CHP (POLARIX) considered but TP53 not in selection criteria. |
Notes
ESCAT IIIB. Gene-level cell — biallelic vs monoallelic distinction matters in MDS/AML (biallelic = TP53-multihit per IPSS-M / ICC 2022, far worse). Per-hotspot cells provided for the most common variants.
Used By
No reverse references found in the YAML corpus.